Patients in the highest PRS quartile had over twofold odds (adjusted OR 2.15) of achieving LDL-C <70 mg/dL or ≥50% reduction compared to the lowest PRS quartile.
Does a European-derived polygenic risk score predict statin-induced LDL-C reduction in young Korean ischemic stroke patients?
A European-derived polygenic risk score for statin response successfully predicts LDL-C reduction in young Korean stroke patients, supporting the cross-ancestry transferability of pharmacogenomic tools.
Absolute Event Rate: 0% vs 0%
Background Q2: 79.3 mg/dL; Q3: 75.4 mg/dL; Q4: 70.2 mg/dL; p<0.001). Percentage reduction increased from 27.5% in Q1 to 32.8% in Q4 (p=0.018). Absolute reduction ranged from 44.9 mg/dL in Q1 to 50.7 mg/dL in Q4 (p=0.021). Patients in the highest PRS quartile (Q4) had more than twofold greater odds of achieving LDL-C <70 mg/dL or ≥50% reduction compared with Q1 (adjusted OR 2.15, 95% CI 1.73–2.67, p<0.001). Each 1-SD increase in PRS corresponded to an additional 2.96 mg/dL LDL-C reduction (95% CI 1.37–4.55, p<0.001), independent of statin intensity. Discussion: A European-derived PRS for on-statin LDL-C response was significantly associated with both absolute and relative LDL-C reduction in young Korean stroke patients These findings support the cross-ancestry transferability of pharmacogenomic prediction tools and highlight their potential role in optimizing lipid-lowering strategies for secondary stroke prevention.
Lee et al. (Thu,) reported a other. Patients in the highest PRS quartile had over twofold odds (adjusted OR 2.15) of achieving LDL-C <70 mg/dL or ≥50% reduction compared to the lowest PRS quartile.